|
1
|
Birkhäuser FD, Kroeger N and Pantuck AJ:
Etiology of renal cell carcinoma: Incidence, demographics, and
environmental factors. Renal Cell Carcinoma: Clinical Management.
Springer Science; New York, NY: pp. 3–22. 2013, View Article : Google Scholar
|
|
2
|
Zhou M and He H: Pathology of renal cell
carcinoma. Renal Cancer. 43:51–69. 2013.
|
|
3
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Najjar YG and Rini BI: Novel agents in
renal carcinoma: A reality check. Ther Adv Med Oncol. 4:183–194.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rohan SM, Xiao Y, Liang Y, Dudas ME,
Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P
and Tickoo SK: Clear-cell papillary renal cell carcinoma: Molecular
and immunohistochemical analysis with emphasis on the von
Hippel-Lindau gene and hypoxia-inducible factor pathway-related
proteins. Mod Pathol. 24:1207–1220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu CZ, Zheng JJ, Bai YH, Xia P, Zhang HC
and Guo Y: HMGB1/RAGE axis mediates the apoptosis, invasion,
autophagy, and angiogenesis of the renal cell carcinoma. Onco
Targets Ther. 11:4501–4510. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhai W, Ma J, Zhu R, Xu C, Zhang J, Chen
Y, Chen Z, Gong D, Zheng J, Chen C, et al: MiR-532-5p suppresses
renal cancer cell proliferation by disrupting the ETS1-mediated
positive feedback loop with the KRAS-NAP1L1/P-ERK axis. Br J
Cancer. 119:591–604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Damayanti NP, Budka JA, Khella HWZ, Ferris
MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN,
Adelaiye-Ogala R, et al: Therapeutic targeting of
TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma.
Clin Cancer Res. 24:5977–5989. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carlo MI, Mukherjee S, Mandelker D, Vijai
J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang
KC, et al: Prevalence of germline mutations in cancer
susceptibility genes in patients with advanced renal cell
carcinoma. JAMA Oncol. 4:1228–1235. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitchell TJ, Rossi SH, Klatte T and
Stewart GD: Genomics and clinical correlates of renal cell
carcinoma. World J Urol. 36:1899–1911. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Emmanuel R, Weinstein S, Landesman-Milo D
and Peer D: eIF3c: A potential therapeutic target for cancer.
Cancer Lett. 336:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sonenberg N and Hinnebusch AG: Regulation
of translation initiation in eukaryotes: Mechanisms and biological
targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou M, Sandercock AM, Fraser CS, Ridlova
G, Stephens E, Schenauer MR, Yokoi-Fong T, Barsky D, Leary JA,
Hershey JW, et al: Mass spectrometry reveals modularity and a
complete subunit interaction map of the eukaryotic translation
factor eIF3. Proc Natl Acad Sci USA. 105:18139–18144. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hinnebusch AG: eIF3: A versatile scaffold
for translation initiation complexes. Trends Biochem Sci.
31:553–562. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hershey JW: The role of eIF3 and its
individual subunits in cancer. Biochim Biophys Acta. 1849:792–800.
2015. View Article : Google Scholar
|
|
18
|
Bhat M, Robichaud N, Hulea L, Sonenberg N,
Pelletier J and Topisirovic I: Targeting the translation machinery
in cancer. Nat Rev Drug Discov. 14:261–278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rothe M, Ko Y, Albers P and Wernert N:
Eukaryotic initiation factor 3 p110 mRNA is overexpressed in
testicular seminomas. Am J Pathol. 157:1597–1604. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scoles DR, Yong WH, Qin Y, Wawrowsky K and
Pulst SM: Schwannomin inhibits tumorigenesis through direct
interaction with the eukaryotic initiation factor subunit c
(eIF3c). Hum Mol Genet. 15:1059–1070. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hao J, Liang C and Jiao B: Eukaryotic
translation initiation factor 3, subunit C is overexpressed and
promotes cell proliferation in human glioma U-87 MG cells. Oncol
Lett. 9:2525–2533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hao J, Wang Z, Wang Y, Liang Z, Zhang X,
Zhao Z and Jiao B: Eukaryotic initiation factor 3C silencing
inhibits cell proliferation and promotes apoptosis in human glioma.
Oncol Rep. 33:2954–2962. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song N, Wang Y, Gu XD, Chen ZY and Shi LB:
Effect of siRNA-mediated knockdown of eIF3c gene on survival of
colon cancer cells. J Zhejiang Univ Sci B. 14:451–459. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li T, Li S, Chen D, Chen B, Yu T, Zhao F,
Wang Q, Yao M, Huang S, Chen Z and He X: Transcriptomic analyses of
RNA-binding proteins reveal eIF3c promotes cell proliferation in
hepatocellular carcinoma. Cancer Sci. 108:877–885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee HY, Chen CK, Ho CM, Lee SS, Chang CY,
Chen KJ and Jou YS: eIF3C-enhanced exosome secretion promotes
angiogenesis and tumorigenesis of human hepatocellular carcinoma.
Oncotarget. 9:13193–13205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao W, Li X, Wang J, Wang C, Jia Y, Yuan
S, Huang Y, Shi Y and Tong Z: Decreasing eukaryotic initiation
factor 3C (eIF3C) suppresses proliferation and stimulates apoptosis
in breast cancer cell lines through mammalian target of rapamycin
(mTOR) pathway. Med Sci Monit. 23:4182–4191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hammes LS, Tekmal RR, Naud P, Edelweiss
MI, Kirma N, Valente PT, Syrjänen KJ and Cunha-Filho JS:
Up-regulation of VEGF, c-fms and COX-2 expression correlates with
severity of cervical cancer precursor (CIN) lesions and invasive
disease. Gynecol Oncol. 110:445–451. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
ANSI/ATCC ASN-0002-2011: Authentication of
Human Cell Lines: Standardization of STR Profiling. ANSI eStandards
Store; 2012
|
|
29
|
Capes-Davis A, Reid YA, Kline MC, Storts
DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A,
et al: Match criteria for human cell line authentication: Where do
we draw the line? Int J Cancer. 132:2510–2519. 2013. View Article : Google Scholar
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Chomczynski P and Sacchi N: Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem.
162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong Z and Zhang JT: Initiation factor
eIF3 and regulation of mRNA translation, cell growth, and cancer.
Crit Rev Oncol Hematol. 59:169–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Asano K, Vornlocher HP, Richter-Cook NJ,
Merrick WC, Hinnebusch AG and Hershey JW: Structure of cDNAs
encoding human eukaryotic initiation factor 3 subunits. Possible
roles in RNA binding and macromolecular assembly. J Biol Chem.
272:27042–27052. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Karásková M, Gunišová S, Herrmannová A,
Wagner S, Munzarová V and Valášek L: Functional characterization of
the role of the N-terminal domain of the c/Nip1 subunit of
eukaryotic initiation factor 3 (eIF3) in AUG recognition. J Biol
Chem. 287:28420–28434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Erzberger JP, Stengel F, Pellarin R, Zhang
S, Schaefer T, Aylett CHS, Cimermančič P, Boehringer D, Sali A,
Aebersold R and Ban N: Molecular architecture of the 40SeIF1eIF3
translation initiation complex. Cell. 158:1123–1135. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Srivastava S, Verschoor A and Frank J:
Eukaryotic initiation factor 3 does not prevent association through
physical blockage of the ribosomal subunit-subunit interface. J Mol
Biol. 226:301–304. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zang Y, Zhang X, Yan L, Gu G, Li D, Zhang
Y, Fang L, Fu S, Ren J and Xu Z: Eukaryotic translation initiation
factor 3b is both a promising prognostic biomarker and a potential
therapeutic target for patients with clear cell renal cell
carcinoma. J Cancer. 8:3049–3061. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sadato D, Ono T, Gotoh-Saito S, Kajiwara
N, Nomura N, Ukaji M, Yang L, Sakimura K, Tajima Y, Oboki K and
Shibasaki F: Eukaryotic translation initiation factor 3 (eIF3)
subunit e is essential for embryonic development and cell
proliferation. FEBS Open Bio. 8:1188–1201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shen J, Yin JY, Li XP, Liu ZQ, Wang Y,
Chen J, Qu J, Xu XJ, McLeod HL, He YJ, et al: The prognostic value
of altered eIF3a and its association with p27 in non-small cell
lung cancers. PLoS One. 9:e960082014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu F, Xu CZ, Gu J, Liu X, Liu R, Huang E,
Yuan Y, Zhao G, Jiang J, Xu C, et al: Eukaryotic translation
initiation factor 3B accelerates the progression of esophageal
squamous cell carcinoma by activating β-catenin signaling pathway.
Oncotarget. 7:43401–43411. 2016.PubMed/NCBI
|
|
41
|
Zhu Q, Qiao GL, Zeng XC, Li Y, Yan JJ,
Duan R and Du ZY: Elevated expression of eukaryotic translation
initiation factor 3H is associated with proliferation, invasion and
tumorigenicity in human hepatocellular carcinoma. Oncotarget.
7:49888–49901. 2016.PubMed/NCBI
|
|
42
|
Qi J, Dong Z, Liu J and Zhang JT: EIF3i
promotes colon onco-genesis by regulating COX-2 protein synthesis
and β-catenin activation. Oncogene. 33:4156–4163. 2014. View Article : Google Scholar
|
|
43
|
Golob-Schwarzl N, Schweiger C, Koller C,
Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C,
Bergler H, Pertschy B, et al: Separation of low and high grade
colon and rectum carcinoma by eukaryotic translation initiation
factors 1, 5 and 6. Oncotarget. 8:101224–101243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen K, Yang J, Li J, Wang X, Chen Y,
Huang S and Chen JL: eIF4B is a convergent target and critical
effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in
Abl transformants. Oncotarget. 7:10073–10089. 2016.PubMed/NCBI
|
|
45
|
Deng J, Lu PD, Zhang Y, Scheuner D,
Kaufman RJ, Sonenberg N, Harding HP and Ron D: Translational
repression mediates activation of nuclear factor kappa B by
phosphorylated translation initiation factor 2. Mol Cell Biol.
24:10161–10168. 2004. View Article : Google Scholar : PubMed/NCBI
|
